These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2894746)

  • 21. Invitation to compliance. The Prolixin brunch.
    Cassino T; Spellman N; Heiman J; Shupe J; Sklebar HT
    J Psychosoc Nurs Ment Health Serv; 1987 Oct; 25(10):15-6, 19. PubMed ID: 3681773
    [No Abstract]   [Full Text] [Related]  

  • 22. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.
    Mandel MR; Severe JB; Schooler NR; Gelenberg AJ; Mieske M
    Arch Gen Psychiatry; 1982 Feb; 39(2):197-203. PubMed ID: 6121543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia.
    Carney MW; Sheffield BF
    Br J Psychiatry; 1976 Nov; 129():476-81. PubMed ID: 990663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients.
    Hertling I; Philipp M; Dvorak A; Glaser T; Mast O; Beneke M; Ramskogler K; Saletu-Zyhlarz G; Walter H; Lesch OM
    Neuropsychobiology; 2003; 47(1):37-46. PubMed ID: 12606844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
    Walker CA
    Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current status of neuroleptic long term treatment of schizophrenia].
    Woggon B; Angst J; Margoses N
    Nervenarzt; 1975 Nov; 46(11):611-6. PubMed ID: 813157
    [No Abstract]   [Full Text] [Related]  

  • 27. Neuroendocrine tests during treatment with neuroleptic drugs. II. The TRH test.
    Braddock LE; Blake IM
    Br J Psychiatry; 1981 Nov; 139():404-7. PubMed ID: 6120732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete ultrarapid metabolism of flupentixol in 42 year old patient suffering from chronic schizophrenia.
    Koch HJ; Zellmer H
    Therapie; 2013; 68(2):117-8. PubMed ID: 23773353
    [No Abstract]   [Full Text] [Related]  

  • 29. How schizophrenic patients change during 3 years' treatment with depot neuroleptics.
    Dencker SJ; Frankenberg K; Lepp M; Lindberg D; Malm U
    Acta Psychiatr Scand; 1978 Feb; 57(2):115-23. PubMed ID: 24982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aftercare of schizophrenic patients: pharmacotherapy and consistency of therapists.
    van der Kolk BA; Goldberg HL
    Hosp Community Psychiatry; 1983 Apr; 34(4):343-8. PubMed ID: 6132867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupenthixol decanoate for a twelve month perioid].
    Pach J; Finkbeiner T; Glaser T; Haug J; Osterheider M; Tegeler J
    Fortschr Neurol Psychiatr; 1998 Oct; 66(10):442-9. PubMed ID: 9825249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression.
    Curson DA; Barnes TR; Bamber RW; Platt SD; Hirsch SR; Duffy JC
    Br J Psychiatry; 1985 May; 146():469-74. PubMed ID: 3893599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
    Wistedt B; Palmstierna T
    J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter controlled trial of fluspirilene and fluphenazine enanthate in chronic schizophrenic syndromes.
    Malm U; Perris C; Rapp W; Wedrén G
    Acta Psychiatr Scand Suppl; 1974; 249():94-116. PubMed ID: 4608506
    [No Abstract]   [Full Text] [Related]  

  • 37. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
    Soni SD; Sampath G; Shah A; Krska J
    Acta Psychiatr Scand; 1992 May; 85(5):354-9. PubMed ID: 1351333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluphenazine and flupenthixol decanoate in psychiatric outpatients practice.
    Coufal J; Novotný M
    Act Nerv Super (Praha); 1981 Dec; 23(4):269-71. PubMed ID: 6121439
    [No Abstract]   [Full Text] [Related]  

  • 39. Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression.
    Gitlin MJ; Nuechterlein KH; Mintz J; Fogelson D; Bartzokis G; Ventura J; Subotnik K; Aravagiri M
    Psychopharmacology (Berl); 2000 Mar; 148(4):350-4. PubMed ID: 10928306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients.
    McEvoy JP; Howe AC; Hogarty GE
    J Nerv Ment Dis; 1984 Jul; 172(7):412-6. PubMed ID: 6144721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.